GlassScriptPhysician profile
Lorien Y Sites
NPI 1578610390
$4,606.56
in general payments reported to CMS, 2019-2025
31 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $226 · 2021: $308 · 2022: $519 · 2023: $427 · 2024: $632 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.49 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $812.94 | 2019-2025 | |
| Abbvie INC. | $657.86 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Leo Pharma INC. | $428.96 | 2019-2025 | Adbry |
| Lilly USA, LLC | $329.03 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Pfizer INC. | $325.92 | 2019-2025 | |
| Genzyme Corporation | $242.14 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $239.32 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Galderma Laboratories, L.P. | $205.59 | 2019-2025 | Nemluvio |
| Allergan, INC. | $161.80 | 2019-2022 | |
| Celgene Corporation | $144.11 | 2019 | |
| Mayne Pharma Commercial LLC | $121.63 | 2019-2025 | |
| Ucb, INC. | $117.03 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $109.02 | 2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $98.03 | 2019-2024 | Libtayo |
| Dermavant Sciences, INC. | $90.18 | 2022-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $85.73 | 2019-2025 | Seysara |
| Sun Pharmaceutical Industries INC. | $78.29 | 2019-2025 | |
| Amgen INC. | $75.42 | 2020-2024 | Otezla |
| Convatec INC. | $35.15 | 2025 | |
| Sandoz INC. | $28.06 | 2019-2020 | |
| Organogenesis INC. | $27.36 | 2023 | Puraply |
| Epi Health, LLC | $26.47 | 2019-2021 | |
| Biofrontera INC. | $24.25 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Medimetriks Pharmaceuticals, INC. | $22.63 | 2019 | |
| Janssen Biotech, INC. | $21.97 | 2025 | Tremfya |
| Incyte Corporation | $18.61 | 2025 | Opzelura |
| Organon LLC | $17.51 | 2025 | Vtama |
| Botanix Sb INC | $17.01 | 2025 | Sofdra |
| Dermira, INC. | $16.04 | 2020 | |
| Journey Medical Corporation | $15.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.91 | 2023 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorien Sites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.